Lasa Supergenerics gains as company to begin trial runs at Unit IV

Lasa Supergenerics rose 3.03% to Rs 136 at 10:12 IST on BSE after the company said it will start its pilot production trial runs at its Unit IV from 25 November 2017.

The announcement was made after market hours yesterday, 22 November 2017.

Meanwhile, the S&P BSE Sensex was up 40.11 points, or 0.12% to 33,601.66. The S&P BSE Small-Cap index was up 125.06 points, or 0.7% to 17,978.54.

On the BSE, 17,596 shares were traded in the counter so far, compared with average daily volumes of 17,000 shares in the past two weeks. The stock had hit a high of Rs 138.60 and a low of Rs 135 so far during the day. The stock hit a record high of Rs 157.80 on 25 September 2017. The stock hit a 52-week low of Rs 125.80 on 28 September 2017.

The small-cap company has equity capital of Rs 22.86 crore. Face value per share is Rs 10.

Lasa Supergenerics said that the company will start its pilot production trial runs at its Unit IV from 25 November 2017. Production and capacity per annum will include Albendazole Intermediate 400MT, Fenbondazole Intermediate 200MT, 2 4 DCP 600MT, Closantel Intermediate 100MT and additionally few components of backward integration for its recent new launches, Lasa Supergenerics said. Regular production will be subject to successful trial, the company said.

Lasa Supergenerics is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chainfrom discovery-to-delivery, with credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012.

Powered by Capital Market - Live News